anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The relationship between MS and ethnicity has been understudied in the Middle East compared to the United States and Europe. As Iran as the highest prevalence of MS in the Middle East, we decided to investigate the demographic and clinical differences in people with MS (pwMS) from major ethnicities Iran.
METHODS: In a cross-sectional study using data from National Multiple Sclerosis Registry in Iran. PwMS from six provinces were chosen and interviewed for determining their ethnicity. Persians (Fars), Kurds, Lurs, Azeris and Arabs with a clear ethnic background were included. Recorded data from the registry was used to compare the demographic and clinical features.
RESULTS: A total of 4015 pwMS (74.2% female) were included in the study with an average age of 36.76 ± 9.68 years. Persians and Kurds had the highest percentage of pwMS in youngest and oldest age groups, respectively, with 2.9% and 5.7% (p<0.01). The highest average age of onset was seen in Persians (29.47 ± 8.89) and the lowest observed in Mazandaranis (26.82 ± 7.68, p<0.01). Azeris and Kurds had the highest proportions of pwMS diagnosed <18 and >55, at rates of 12% and 1.6%, respectively (p<0.01). There were statistically significant differences in distribution of phenotypes (p<0.01) and time to progression to secondary progressive MS (p<0.01) such that Persians had the highest rate of clinically isolated syndrome (CIS) at 19.3% and Arabs had highest rates of relapsing-remitting MS (86.2%) and secondary progressive MS (16.4%). Lurs, Azeris and Mazandaranis had significantly more patients progressing to secondary-progressive MS <5 years from diagnosis (p<0.01). There was a significant difference in number of relapses between the ethnicities (p<0.01) with Lurs having the highest proportion of participants reporting >4 relapses with 23.0% and Azeris having the highest percentage of pwMS reporting no relapse (53.0%). Kurds had the highest Expanded Disability Status Scale (EDSS) average at 2.93 ± 1.99 and Lurs had the lowest with 1.28 ± 1.25 (p<0.01). The differences in prevalence of positive family history for the whole cohort between ethnicities were significant (P=0.02), ranging from 12.8% in Kurds to 19.6% in Persians.
CONCLUSION: We found Persians to have higher rates of pediatric MS and higher rates of CIS. Kurds and Lurs had higher and lower EDSS scores, respectively. Lurs and Persian had higher annual relapse rates. We also found lower rates of SPMS among Arabs and earlier progression to SPMS in Lurs, Azeris and Mazandaranis. Such differences highlight the importance of the potential role of ethnicities in diagnosis and prognosis of MS, especially considering their observation within the geographical limits of a single country.
The main intervention of this study is 89Zr-atezolizumab PET-scan combined with a low-dose CT-scan. The PET/CT scan will be performed before infusion of CAR T-cell therapy. In patients with an end-of-treatment F-FDG positive PET-signal a second 89Zr-atezolizumab PET/CT-scan will be performed.
This article analyzes the publications of women who suffer from Polycystic Ovary Syndrome (PCOS) in Facebook groups. PCOS is a metabolic syndrome experienced by a vast number of women of childbearing age. Some of its main symptoms are acne, weight gain, and unwanted hair. On the other hand, the treatment focuses on changing the lifestyle associated with diet control and adopting new habits. The analysis of statements and pictures posted by the participants of the groups, which express their before-after transformations, reveals that diagnosis, treatment, and perception of PCOS are currently deeply associated with aesthetic factors. Finally, we discuss how this event is linked to the historically produced binary gender pattern centered on body differences and how it illustrates the emphasis on self-enhancement, especially concerning its expression in body and aesthetic standards.
Enteric elastomers and related methods are generally provided. In some embodiments, the enteric elastomer is a polymer composite. Certain embodiments include polymer composites in which hydrogen bonds within two carboxyl-containing polymers crosslink the polymer network into an elastic and pH-responsive polymer composite. Advantageously, the polymer composite has the ability to be stable and elastic in acidic environments (e.g., gastric environments) but soluble in neutral pH environments (e.g., small and large intestine environments). In some embodiments, the polymer composites described herein comprise a mixture of two or more polymers having carboxyl functionality such that the two or more polymers form hydrogen bonds. In certain embodiments, the polymer composite has enteric properties and elasticity.
OZURDEX® is a sterile intravitreal implant containing 0.7 mg (700 mcg) dexamethasone in the NOVADUR® solid polymer sustained-release drug delivery system which does not contain an antimicrobial preservative.

OZURDEX® is preloaded into a single-use, DDS® applicator to facilitate injection of the rodshaped implant directly into the vitreous. The NOVADUR® system contains two poly D,L-lactide-co-glycolide (PLGA) polymer excipients. Both of these polymer materials have the same PLGA backbone, but the terminal end groups differ between them. One polymer, Resomer® RG 502, is ester terminated, and the other Resomer® RG 502 H is acid terminated. The chemical name for dexamethasone is Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-. Its structural formula is: 

MW 392.47; molecular formula: C22H29FO5

Dexamethasone occurs as a white to cream-colored crystalline powder having not more than a slight odor, and is practically insoluble in water and very soluble in alcohol.

The PLGA matrix slowly degrades to lactic acid and glycolic acid.
The invention relates to a hair treatment agent containing alkoxylated silicones and cationic silicones. In modern hair care products, attempts have increased to apply the product onto the keratin fibers in the form of a foam. For this purpose, the foam should be creamy and have fine pores while simultaneously having a specified volume and being stable such that the foam is stable while being worked into the keratin fibers. Until now, these requirements have been met only by using large quantities of surfactants and/or propellant gases. This type of application is further complicated if no propellant gas is to be used but rather the foam is to be produced by means of special nozzles in pump applicators. In the process, foams are frequently obtained which are only relatively aqueous, have large pores, and are not very stable. This is increasingly the case the more hair care ingredients are included in the aqueous composition. One aim of the invention is therefore to prevent the aforementioned disadvantages of the prior art. Together with the production of a fine-pore, creamy, and stable foam, side effects of environmental influences and of oxidative as well as surfactant hair treatments are to be reduced preferably during the oxidative or surfactant hair treatment but also after the oxidative or surfactant hair treatment without impairing the effectiveness of the oxidative or surfactant cosmetics, in particular with respect to color intensity, color fastness, lightening power, or waving effect, and while preventing oil buildup of the keratin fibers and the increased formation of dandruff.
The newer antiplatelet agents such as Ticagrelor have demonstrated superiority to Clopidogrel in patients presenting with acute coronary syndrome (ACS). At present Ticagrelor remains a first line therapy as an adjunct to aspirin for patients undergoing primary PCI for STEMI for reducing major adverse events. However, the safety and efficacy of Ticagrelor has not been investigated in patients with STEMI post fibrinolysis. Ticagrelor results in significantly higher platelet inhibition than aspirin or clopidogrel and may expose patients to an increased risk of bleeding if administered post thrombolysis. However, fibrinolytic therapy itself results in a prothrombotic milieu with greater activation of platelets, a condition that can be balanced with addition of stronger antiplatelet agents. Similar concerns were initially reflected for clopidogrel as an adjunct to fibrinolytic therapy but were later proven to be unsubstantiated. In fact, adjunct administration of clopidogrel to fibrinolytic therapy reduces major adverse events as shown by multiple studies and has become the standard of care recommended by guidelines. The present study is proposed to study the safety and efficacy of Ticagrelor in patients undergoing PCI post fibrinolytic therapy for STEMI.
A 20-year-old quarter horse gelding was presented for routine dental examination. Periodontal disease and luxation of tooth 108 was diagnosed and oral extraction was planned. After an unsuccessful blind maxillary nerve block, it was elected to perform the procedure under total intravenous anesthesia. Following recovery, a focal superficial corneal ulcer, severe retrobulbar swelling, mild exophthalmos, and marked swelling and prolapse of the third eyelid (nictitating membrane) were observed. Clinical signs persisted beyond 48 h despite the use of systemic anti-inflammatories and topical ocular anti-inflammatories and antibiotics. A temporary tarsorrhaphy was subsequently done at 48 h and the horse was discharged after 5 d of hospitalization and regression of clinical signs. Although it is very useful for easing dental extractions, the blind maxillary nerve block is associated with potential complications due to inadvertent vascular puncture. This case report describes a rare complication of prolapse of the third eyelid in a horse after a maxillary nerve block and successful treatment with a temporary tarsorrhaphy. Key clinical message: This case report explains how nictitating membrane swelling and prolapse can occur following a blind maxillary nerve block in the horse and describes treatment with a temporary tarsorrhaphy.
The invention belongs to the technical field of medicaments and provides active ingredients of Chinese herbal medicine camptosorus sibiricus and an extraction method and use of the same. The extraction method comprises a water extraction method, an alcohol extraction method, a macroporous resin purification method and a solvent extraction method. The main active ingredients of an extract obtained by the method are total flavonoids, total momordica saponins and total organic acids, wherein the content of the total flavonoids is 1 to 35 percent, the content of the total momordica saponins is 1 to 25 percent and the content of the total organic acids is 1 to 3 percent. The invention also provides a method for preparing the camptosorus sibiricus into a proper formulation directly or by mixing with solid or liquid commonly used for preparations of the type in pharmaceutics. The active ingredients of the camptosorus sibiricus and the preparation thereof have functions of treating thromboangiitis obliterans, nephritis, traumatism and bleeding, metrorrhagia, neurodermitis, hemiplegia caused by cerebral embolism and diabetes-related complications. The extraction method is simple, easy to implement and low in cost. And the extract obtained is free from toxic and side effects.
FIELD: medicine. SUBSTANCE: desired products are prepared by ethynylation of 2-methyl-trans-decahydroquinolone-4. The process is carried out at 70-75 C in liquid ammonia in the presence of potassium hydroxide. Said process is followed by methylation with mixture of formaldehyde and formic acid and by neutralization of reaction mixture with potassium carbonate. Desired product is then isolated in free form or as salt. EFFECT: improves efficiency of method.
Participants will wait 4 weeks before starting the M2M program. Participants will be instructed to resume their normal daily activities during the wait-period.
OBJECTIVE: Surgery for obstetric fistula is a highly effective treatment to restore continence and improve quality of life. However, a lack of data on the cost-effectiveness of this procedure limits prioritization of this essential treatment. This study measures the effectiveness of fistula surgeries using disability-adjusted life years (DALYs) averted.
METHODS: In 2021 and 2022, the Fistula Foundation funded 20 179 fistula surgeries and related procedures at 143 hospitals among 27 countries. We calculated DALYs averted specifically for vesicovaginal fistula and rectovaginal fistula procedure types (n = 13 235 surgeries) by using disability weights from the 2019 Global Burden of Disease study. We based cost calculations on direct treatment expenses, including medical supplies, health provider fees, and preoperative and postoperative care. We measured effectiveness using data on the risk of permanent disability, country-specific average life spans, and treatment outcomes.
RESULTS: The total treatment cost was $7.6 million, and a total of 131 433 DALYs were averted. Thus, the cost per DALY averted-the cost to restore 1 year of healthy life-was $58. For this analysis, we took a cautious approach and weighted only surgeries that resulted in a closed fistula with restored continence. We calculated DALYs averted by country. Limitations of the study include data entry errors inherent in patient logs and lack of long-term outcomes.
CONCLUSION: The current study demonstrates that obstetric fistula surgery, along with having a significant positive impact on maternal health outcomes, is highly cost-effective in comparison with other interventions. The study therefore highlights the benefits of prioritizing fistula treatment as part of the global agenda for maternal health care.
Permethrin Cream 10 % also contains the active ingredient permethrin, but in double the concentration, and otherwise corresponds to the approved standard therapeutic agent InfectoScab 5 % Cream in terms of the main other ingredients. This is also used for the topical treatment of scabies, as well as for re-creaming, e.g. after washing hands.
FIELD: medicine. SUBSTANCE: method involves extracting lyophilic dried cells of Dioscorea deltoidea tissue culture in water in 1:(10-20) proportion during 2-3 h. The sediment is separated by centrifuging and the extraction process repeated. Ammonium sulfate is added to the joint supernatant until complete saturation takes place and the mixture is allowed to stand during 30 min resulting in precipitation of both high and low molecular weight glycosides. The obtained precipitate is 5-6 times treated with 96% ethanol and the precipitate is separated, washed with ethanol, the supernatant liquid is fully evaporated in rotor-type vaporizer. Oligofurostanozides purity in the residue is 65% The produced preparation is repeatedly treated with several portions of 96% ethanol and the precipitate is separated and vaporized. The preparation purity is 80% Oligofurostanozides output is 50% of the theoretically expected one. EFFECT: accelerated process; increased output of the end product.
Research shows that fish oil and its component fatty acids EPA and DHA provide health benefits such as reducing the risk of cardiac death and lowering inflammation. Yet a large portion of the population is not consuming the recommended amount of fish due to high cost, dietary restrictions such as vegetarianism/veganism, concerns about high levels of mercury, general dislike, and other factors. Additionally, to meet the recommendations fish and fish oil production present sustainability challenges. A potential alternative is to utilize EPA and DHA from algae. These sustainable oils can be added to foods increasing the potential for fatty acids to counteract chronic disease and increasing access to general consumers. Previously, our lab has developed, and optimized EPA and DHA fortified non-dairy plant milk beverages utilizing algae oil emulsions (food grade). Up to 0.4% algae oil can be added to soymilk with limited changes to overall liking. This study will compare the algae oil fortified soymilk to a commercial algae oil capsule containing the same base oil with the goal of demonstrating equivalent or greater accumulation of EPA and DHA in blood lipid pools. Subjects will consume either one beverage or two capsules per day, containing equivalent amounts of EPA and DHA. Blood will be taken at 4 time points throughout the 6 week study, every two weeks and analyzed for EPA and DHA in different lipid types. Additionally, participants will complete a food frequency questionnaire to evaluate their normal diet, sensory evaluation (overall liking, and attribute evaluation) of the beverages, and daily symptom and intake logs to track consumption and any side effects.
The experimental extremity will be assigned randomly and will receive a single treatment session of TrP sham dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, sham dry needling technique will be performed on the TrP for 60 seconds with a needle without tip.
Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.
A computing device for processing image data in a medical evaluation workflow is described. The computing device receives image data of a patient and metadata associated with the image data. The computing device analyzes pixel information of the image data using a particular machine learning algorithm to determine one or more acquisition conditions. The computing device selects a machine learning algorithm from a set of machine learning algorithms based on the determined one or more acquisition conditions. The particular machine learning algorithm is different from each machine learning algorithm of the set of machine learning algorithms. The computing device analyzes the pixel information of the image data and the metadata using the selected machine learning algorithm to determine one or more medical conditions of the patient.
The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.
Patients scheduled for aortic operation (n=20+100) in Kuopio University Hospital. Aortic tissue samples and blood will be collected for analysis and compared to 4D flow MRI parameters. Control samples will be collected from healthy organ donors (n=5+5) operated in Kuopio University Hospital.
While most individuals with PTSD treated with cognitive behavioral therapy (CBT) show improvement, they still have some enduring symptoms and functional impairment. Accordingly, there is a need for treatment advances. D-cycloserine (DCS), an antibiotic that has been used for over 50 years, has also been found to have positive effects on cognition and anxiety. DCS was found to enhance learning and memory, and also facilitates extinction of fear reactions. However, DCS only produces an extinction effect when paired with behavioral training, not when simply given alone. Thus, the medication only needs to be given for seven doses in this research and youth do not need to take the medication long term. The research also includes a three-month follow-up.
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).
METHODS: We conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.
RESULTS: From 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.
CONCLUSIONS: Adding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.
PURPOSE:To provide a cosmetic safe to human bodies, free from greasiness on the skin, having both of humectant effect and skin-smoothing effect, also excellent in skin-beautifying, ultraviolet light absorbing and skin aging-preventive effects. CONSTITUTION:This cosmetic consists of intact water extract or organic solvent extract of rice or a material containing such extracts. The cosmetic can be obtained by the following process: rice is crushed or ground into powder; water is added thereto followed by heating to boil; or at first, hot water is added thereto and carried out to extract to obtain a water extract, which is, if desired, put to squeezing and filtration to obtain a clear extract. An organic solvent (pref. to be safe even if administered to human bodies, e.g. ethyl alcohol) may be used in place of hot water and the extract exhibits a comparable effect.
Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in patients with advanced HCC and CPB7 cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo. Patients will be randomly assigned in a 2:1 ratio to treatment with oral doses of either namodenoson 25 mg or matching placebo administered twice daily for consecutive 28-day cycles. Patients will be evaluated regularly for safety. Tumor imaging will be performed every two cycles. Treatment will continue until the patient experiences PD or unacceptable drug-related intolerability. Patients will return for a follow-up visit 28 days after completion of the last dose of study drug, and survival data will be obtained for all randomized patients who consent to long-term follow-up. Patients who discontinue dosing and consent to follow-up will be followed indefinitely for survival status.

Once the requisite number of events has been observed and the blind is broken for analysis of the trial results, any surviving patients who remain on blinded drug will be offered the opportunity to continue dosing with OL namodenoson 25 mg twice daily indefinitely.